New trials, publications, preprints and grants on this target, month by month.
Trial
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation
6 Jun 2027· PHASE2_PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
1 Jun 2027· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
TCR1188-ABC Cells in KRAS-mutated Cancers
1 Dec 2026· PHASE1 · RECRUITING· CTGOV
Publication
Development and Validation of an UPLC-QqQ MS/MS Method for the Determination of Daraxonrasib, a New pan-KRAS Inhibitor, in Dog Plasma and Whole Blood and Its Application to Pharmacokinetic Studies.
1 Dec 2026· Biomedical chromatography : BMC· PUBMED
Trial
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
11 Nov 2026· PHASE1_PHASE2 · SUSPENDED· CTGOV
Publication
Toxoplasma gondii GRA16-induced apoptosis in KRAS-mutant colorectal cancer cells is linked to coordinated p53 and PP2A-B55 signaling.
6 Nov 2026· Parasites, hosts and diseases· PUBMED
Publication
Simultaneous LC-MS/MS quantification of four KRAS inhibitors (RMC-6236, RMC-9805, RMC-7977, and MRTX1133) in human plasma: toward therapeutic drug monitoring in pancreatic ductal adenocarcinoma.
5 Nov 2026· Bioanalysis· PUBMED
Publication
CRIP1 Promotes Ovarian Cancer Progression by Mediating the KRAS-USP7 Interaction and Stabilizing KRAS.
5 Nov 2026· Reproductive sciences (Thousand Oaks, Calif.)· PUBMED
Publication
Uncovering KRAS-mutant allele-specific biology and vulnerabilities in non-small cell lung cancer.
4 Nov 2026· The Biochemical journal· PUBMED
Publication
ROCK2 inhibitor belumosudil overcomes resistance to KRAS inhibition in pancreatic cancer models.
3 Nov 2026· JCI insight· PUBMED
Publication
KRAS G12Y Causing a False-Positive KRAS G12C Result With an Indistinguishable PCR Pattern in Lung Adenocarcinoma.
2 Nov 2026· Respirology case reports· PUBMED
Publication
Saturation mutagenesis library screening identifies on-target secondary resistance mutations in KRASG12D-selective inhibitors.
2 Nov 2026· Cancer letters· PUBMED
Publication
EML4-ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway.
2 Nov 2026· Cancer discovery· PUBMED
Publication
Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer.
2 Nov 2026· Cancer discovery· PUBMED
Trial
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer
1 Nov 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
ASO Visual Abstract: KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer.
1 Nov 2026· Annals of surgical oncology· PUBMED
Publication
Divergent Roles of PIK3C3 in KRAS-Wild-Type and KRAS-Mutant Advanced Colorectal Cancer: Implications for 5-Fluorouracil Sensitivity and Prognosis.
1 Nov 2026· Cancer medicine· PUBMED
Publication
Identification of a Novel KRAS::ETNK1 Fusion Transcript in a Myelodysplastic/Myeloproliferative Overlap Syndrome With Eosinophilia: A Case Report.
1 Nov 2026· EJHaem· PUBMED
Publication
Combination of canagliflozin and adagrasib as a novel targeted therapy for LKB1-KRASG12C co-mutated NSCLC.
1 Nov 2026· Cancer letters· PUBMED
Trial
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
31 Oct 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
31 Oct 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
KRAS-mutated non-small cell lung cancer (NSCLC) in South India: Real-world genomic landscape, treatment patterns, and outcomes.
31 Oct 2026· Lung India : official organ of Indian Chest Society· PUBMED
Publication
KRAS in pancreatic cancer: from molecular biology to transformative therapeutics.
30 Oct 2026· Journal of hematology & oncology· PUBMED
Publication
Intrinsic resistance to KRAS inhibition: Interfering with interferon.
29 Oct 2026· Cancer cell· PUBMED
Publication
KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer.
29 Oct 2026· Cancer cell· PUBMED
Publication
Oncogenic KRAS Suppresses IFNγ Signaling in Tumor Cells.
28 Oct 2026· Cancer immunology research· PUBMED
Publication
Divarasib Bests 1st-Generation KRASG12C Inhibitors.
27 Oct 2026· Cancer discovery· PUBMED
Publication
Tumor-associated Macrophages Promote Adaptive Tolerance in KRAS G12C-mutant Lung Cancer Cells by Secreting TGF-β1.
27 Oct 2026· Anti-cancer agents in medicinal chemistry· PUBMED
Trial
MRD Monitoring in Colorectal Cancer Using ctDNA
26 Oct 2026· NA · RECRUITING· CTGOV